News
ETON
11.98
-0.13%
-0.02
Eton Pharmaceuticals Price Target Raised to $18.00/Share From $15.00 by Craig-Hallum
Dow Jones · 15m ago
Eton Pharmaceuticals Is Maintained at Buy by Craig-Hallum
Dow Jones · 15m ago
The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts
Benzinga · 17m ago
Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $18
Benzinga · 24m ago
Eton Pharmaceuticals price target raised to $18 from $15 at Craig-Hallum
TipRanks · 3h ago
Craig-Hallum Keeps Their Buy Rating on Eton Pharmaceuticals (ETON)
TipRanks · 4h ago
Eton Pharmaceuticals Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 2d ago
Eton Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
Weekly Report: what happened at ETON last week (1230-0103)?
Weekly Report · 2d ago
HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $17
Benzinga · 2d ago
Strategic Acquisition of Galzin Boosts Eton Pharmaceuticals’ Long-Term Growth Prospects and Raises Price Target
TipRanks · 2d ago
Eton Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
TipRanks · 2d ago
ETON PHARMACEUTICALS INC <ETON.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $17 FROM $15
Reuters · 2d ago
Eton acquires Wilson disease drug Galzin
Seeking Alpha · 5d ago
ETON PHARMACEUTICALS INC - PURCHASES GALZIN FOR $7.0 MILLION PLUS $0.2 MILLION FOR INVENTORY
Reuters · 5d ago
Eton Pharmaceuticals acquires Galzin
TipRanks · 5d ago
Eton Pharmaceuticals Acquires Galzin For Terms Undisclosed, Expands Rare Disease Treatment Portfolio
Benzinga · 5d ago
*Eton Pharmaceuticals Sees Assuming Commercializating Galzin in U.S. in 1Q >ETON
Dow Jones · 5d ago
ETON PHARMACEUTICALS INC: HAS ALSO ACQUIRED EUROPEAN RIGHTS TO GALZIN
Reuters · 5d ago
ETON PHARMACEUTICALS INC - TO COMMERCIALIZE GALZIN IN U.S. IN Q1 2025
Reuters · 5d ago
More
Webull provides a variety of real-time ETON stock news. You can receive the latest news about Eton Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About ETON
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.